Beverly S. Mitchell, M.D.

Clinical Focus

• Cancer> Hematology
• Cancer> Hematology> Hematologic Malignancies
• Cancer> Lymphoma
• Hematology

Administrative Appointments

• Director, Stanford Cancer Institute (2008 - present)
• Deputy Director, Stanford Cancer Center (2005 - 2008)

Honors and Awards

• President, American Society of Hematology (2001)
• Member, American Society for Clinical Investigation (to present)
• Member, Association of American Professors (1991)
• Stohlman Award, Leukemia Society of America (1988)
• National Academy of Sciences, Institute of Medicine (Inducted 2001)

Professional Education

Postdoctoral Advisees

Le Xuan Truong Nguyen,  Manali Patel

Graduate & Fellowship Program Affiliations

• Cancer Biology

Current Research Interests

Beverly S. Mitchell, MD, is the Director of the Stanford Cancer Institute and is the George E. Becker Professor of Medicine at Stanford University. Before joining the Stanford faculty, Dr. Mitchell lead the Molecular Therapeutics Program at UNC Chapel Hill's Lineberger Comprehensive Cancer Center, where she also served as Associate Director for Translational Research and Chief of the Division of Hematology/Oncology.

Dr. Mitchell received a bachelors degree in biochemistry from Smith College in Massachusetts and received her MD from Harvard Medical School. She completed her medical training as Chief Resident at the University of Washington. After completing a research fellowship at the Metabolic Laboratory at the University of Zurich in Switzerland she was awarded a Hematology Fellowship at the University of Michigan. Dr. Mitchell was a faculty member in the Departments of Medicine and Pharmacology at the University of Michigan for 16 years before moving to UNC.

Dr. Mitchell has authored over 130 peer-reviewed articles. She served as President of the American Society of Hematology (ASH) and was Chair of the Medical and Scientific Affairs Committee and Vice Chair for Medical and Scientific Affairs of the Leukemia and Lymphoma Society of America.

Dr. Mitchell's research relates to the development of new therapies for hematologic malignancies. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.

Publications

• Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53. Huang M, Whang P, Lewicki P, Mitchell BS. Mol Pharmacol. 2011; 80 (1): 40-8
• Effect of nucleophosmin1 haploinsufficiency on hematopoietic stem cells. Raval A, Kusler B, Pang WW, Weissman IL, Mitchell BS, Park CY. Leukemia. 2011
• Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. Huang M, Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, Felsher DW, Mitchell BS. J Biol Chem. 2011; 286 (13): 11035-46
• Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Huang M, Itahana K, Zhang Y, Mitchell BS. Cancer Res. 2009; 69 (7): 3004-12
• Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. Huang M, Wang Y, Gu J, Yang J, Noel K, Mitchell BS, Schramm VL, Graves LM. Leuk Res. 2008; 32 (8): 1268-78